Close

Search

Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
share
Email Facebook Twitter Google+ LinkedIn Comments

LaserSight Files PMA Supplement for Mixed Astigmatism Treatment

Photonics.com
Mar 2001
WINTER PARK, Fla., Mar. 12 -- LaserSight Inc. has filed a PMA Supplement with the US Food and Drug Administration requesting approval to use its LaserScan LSX excimer laser system to perform LASIK treatment of mixed astigmatism with the astigmatic component in the range of + 0.5 to + 6.0 diopters. LaserSight now has five PMA Supplements under active consideration by the FDA.
   "We are continuing to file PMA Supplements that, when approved, will allow refractive surgeons using our LaserScan LSX system to treat a broad range of refractive error using the same advanced state-of-the-art precision beam microspot scanning technology the company has provided to its international customers for over two years," said Michael R. Farris, president and CEO of LaserSight. "Since May 1998, LaserSight's international customers have been using their LSX systems to treat the entire range of refractive errors including myopia, hyperopia, astigmatism and mixed astigmatism."

News & Featureslasers

Comments
Terms & Conditions Privacy Policy About Us Contact Us
back to top
Facebook Twitter Instagram LinkedIn YouTube RSS
©2018 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA, info@photonics.com

Photonics Media, Laurin Publishing
x We deliver – right to your inbox. Subscribe FREE to our newsletters.
We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.